VolitionRx reports Q1 revenue $170,000, consensus $390,000.

Cash and cash equivalents as of March 31 totaled approximately $11.8M. Cameron Reynolds, President and Group CEO of Volition said: “Throughout this quarter we have continued to work on a number of opportunities with the aim of ensuring Volition is cash flow neutral in 2025 with a mix of non-dilutive funding, revenue growth and milestone payments from out licensing, as we already achieved in our Volition Vet subsidiary, and through further cost reduction measures targeting $10M in annualized reductions. We are making strong and necessary decisions to preserve capital in the company whilst ensuring we deliver on our vision and mission. We believe that we are now close to receiving large amounts of data for both Nu.Q NETs and Capture-PCR and consequently, subsequent to quarter end, we are taking some necessary actions to significantly reduce expenditures and cash burn as we concentrate on commercialization.”